Adagio Medical Holdings, Inc. (NASDAQ:ADGM) shares are up during Monday’s premarket session following the announcement of positive pivotal results for its vCLAS Ventricular Ablation System.

The company on Sunday said the trial demonstrated equivalent effectiveness in treating both ischemic and non-ischemic cardiomyopathy using an endocardial-only approach.

Adagio Medical Stock Jumps On vCLAS Pivotal Trial Results

The heart medical device company on Sunday reported six-month results from its FULCRUM-VT Investigational Device Exemption clinical trial, which demonstrated significant safety and effectiveness endpoints.

The results showed an 84% freedom from shock and a 59% freedom from ventricular tachycardia recurrence, which may be driving investor interest as the company seeks FDA approval for its technology, contributing to the stock’s upward movement.

Read Also:

Also Read: Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, ...